INPEFA® is an inhibitor of SGLT2 and SGLT1 for adults with heart failure or T2 Diabetes, CKD, and other CV risk factors. See Safety Info and full Prescribing Information.

Asserts that INPEFA significantly reduced the risk of CV death, hospitalization for HF, and urgent HF visit when compared to placebo as evaluated in SOLOIST‑WHF

A multi-center, randomized, double-blind, placebo-controlled, Phase 3 study in 10,584 patients with T2DM, CKD, and additional CV risk factors, evaluating the HF outcomes of INPEFA versus placebo …

Learn about the financial support options and helpful resources that INPEFA® offers your patients, like the 30-day voucher and copay card. See Important Safety Information and full Prescribing Information.

Learn how INPEFA® was studied in patients with heart failure and view information about the SOLOIST-WHF trial. See Important Safety Information and full Prescribing Information.

All patients receive a voucher for a free 30-day supply* of INPEFA as prescribed by their doctor. Enrollment in the 30-Day Voucher Program triggers support through INPEFA TogetherTMM.

If you don't have insurance or your insurance doesn't cover INPEFA, you may still get help paying for INPEFA. Talk to your dedicated INPEFA TogetherTM Support Specialist to learn more.

INPEFA increases the risk of ketoacidosis in patients with type 1 diabetes mellitus (T1DM). Type 2 diabetes mellitus (T2DM) and pancreatic disorders are also risk factors.

Derived From: Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie …